Titan Biotech Limited (BOM:524717)
366.40
+16.80 (4.81%)
At close: Nov 9, 2026
Titan Biotech Revenue
Titan Biotech had revenue of 764.63M INR in the quarter ending September 30, 2026, with 40.67% growth. This brings the company's total for the last twelve months to 2.41B, up 38.25% year-over-year. In the fiscal year ending March 31, 2026, Titan Biotech had annual revenue of 2.06B with 31.79% growth. That makes Titan Biotech the 32,360th largest company in the world by revenue and 2,415th in India.
Revenue (ttm)
2.41B
Revenue Growth
+38.25%
P/S Ratio
7.85
Revenue / Employee
4.57M
Employees
527
Market Cap
18.92B
Revenue by Geography
- India 1.26B 61.0%
- Overseas 803.32M 39.0%
Fiscal year ended Mar 31, 2026 See the full Titan Biotech breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 2.06B | 497.40M | 31.79% |
| Mar 31, 2025 | 1.56B | -76.21M | -4.65% |
| Mar 31, 2024 | 1.64B | 200.73M | 13.94% |
| Mar 31, 2023 | 1.44B | 204.50M | 16.55% |
| Mar 31, 2022 | 1.24B | -186.92M | -13.14% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Brightcom Group | 72.25B |
| Sagar Cements | 27.89B |
| Venus Remedies | 8.37B |
| Syncom Formulations (India) | 4.98B |
| Nibe Limited | 4.55B |
| Poojaa Precision Engg. | 3.80B |
| Menon Bearings | 3.54B |
| Hindusthan Insulators & Industries | 3.39B |